A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes, providing ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

A study explored glucagon metabolism in humans with and without Type 1 diabetes using stable glucagon tracers. Findings reveal significant differences in splanchnic and leg glucagon metabolism.

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 ...

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

The mechanisms driving the cardiovascular and renal benefits of therapies targeting intestinal hormones in type 2 diabetes ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A novel study using stable glucagon tracers reveals key findings in Type 1 diabetes metabolism, impacting treatment and management strategies.